Tags

Type your tag names separated by a space and hit enter

Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease.
Int J Chron Obstruct Pulmon Dis 2019; 14:1779-1787IJ

Abstract

Despite maximal medical therapy, a subset of patients with chronic obstructive pulmonary disease continue to suffer acute exacerbations. It is also clear that a subset of this population has elevated blood eosinophils. In addition to clearly responding better to inhaled corticosteroids, it is also possible that this subgroup may benefit from biologic treatments targeting eosinophilic inflammation. Mepolizumab, a humanized monoclonal antibody against interleukin-5 (IL-5), may have a therapeutic effect in a subgroup of patients with COPD and eosinophilic airway inflammation. In this review, we discuss the biologic rationale for mepolizumab targeting IL-5 in eosinophilic COPD as well as the results of recently published clinical trials.

Authors+Show Affiliations

Lung Health Center, Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.Lung Health Center, Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31496677

Citation

Mkorombindo, Takudzwa, and Mark T. Dransfield. "Mepolizumab in the Treatment of Eosinophilic Chronic Obstructive Pulmonary Disease." International Journal of Chronic Obstructive Pulmonary Disease, vol. 14, 2019, pp. 1779-1787.
Mkorombindo T, Dransfield MT. Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2019;14:1779-1787.
Mkorombindo, T., & Dransfield, M. T. (2019). Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease, 14, pp. 1779-1787. doi:10.2147/COPD.S162781.
Mkorombindo T, Dransfield MT. Mepolizumab in the Treatment of Eosinophilic Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2019;14:1779-1787. PubMed PMID: 31496677.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease. AU - Mkorombindo,Takudzwa, AU - Dransfield,Mark T, Y1 - 2019/08/07/ PY - 2019/04/05/received PY - 2019/07/10/accepted PY - 2019/9/10/entrez PY - 2019/9/10/pubmed PY - 2019/9/10/medline KW - COPD KW - acute exacerbations of COPD KW - eosinophils KW - mepolizumab SP - 1779 EP - 1787 JF - International journal of chronic obstructive pulmonary disease JO - Int J Chron Obstruct Pulmon Dis VL - 14 N2 - Despite maximal medical therapy, a subset of patients with chronic obstructive pulmonary disease continue to suffer acute exacerbations. It is also clear that a subset of this population has elevated blood eosinophils. In addition to clearly responding better to inhaled corticosteroids, it is also possible that this subgroup may benefit from biologic treatments targeting eosinophilic inflammation. Mepolizumab, a humanized monoclonal antibody against interleukin-5 (IL-5), may have a therapeutic effect in a subgroup of patients with COPD and eosinophilic airway inflammation. In this review, we discuss the biologic rationale for mepolizumab targeting IL-5 in eosinophilic COPD as well as the results of recently published clinical trials. SN - 1178-2005 UR - https://www.unboundmedicine.com/medline/citation/31496677/Mepolizumab_in_the_treatment_of_eosinophilic_chronic_obstructive_pulmonary_disease L2 - https://dx.doi.org/10.2147/COPD.S162781 DB - PRIME DP - Unbound Medicine ER -